Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Keen Hun Tai"'
Autor:
David R. H. Christie, James W. Denham, John Attia, Judy Murray, Gillian M. Duchesne, Christopher Oldmeadow, Sandra Turner, Lizbeth Kenny, Brett Delahunt, Allison Steigler, Nirdosh Kumar Gogna, Keen Hun Tai, David Joseph, Tom Shannon, Annette Haworth, John Stanley, John H L Matthews, Rachel Kearvell, Nigel Spry, Chris Atkinson, Martin A. Ebert, David Lamb
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 106:693-702
To clarify the relative effects of duration of androgen suppression (AS) and radiation dose escalation (RDE) on distant progression (DP) in men with locally advanced prostate cancer.Participants with locally advanced prostate cancer in the TROG 03.04
Publikováno v:
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, Vol 30, Iss, Pp 65-70 (2021)
Clinical and Translational Radiation Oncology, Vol 30, Iss, Pp 65-70 (2021)
Highlights • Risks with tight adaptive RT margins. • Cancer control may be poorer if margins tight. • Prospective studies required.
Background and Purpose To report long-term outcomes of online image-guided (IG) adaptive radiation therapy
Background and Purpose To report long-term outcomes of online image-guided (IG) adaptive radiation therapy
Autor:
Nathan Lawrentschuk, Michael S Hofman, Andrew Lim, Daniel Moon, Cristian Udovicich, Keen Hun Tai, Declan G. Murphy, Mathias Bressel, Mark Shaw, Shankar Siva, Jeremy Goad, Lisa Selbie, John Violet, Sarat Chander, Farshad Foroudi, Tomas Kron
Publikováno v:
European Urology. 74:455-462
Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment option for oligometastatic prostate cancer. However, limited prospective evidence is available. Objective To determine the safety and feasibility of single fraction SA
Publikováno v:
Radiotherapy and Oncology. 161:S685
Autor:
Scott Williams, Sweet Ping Ng, Gillian M. Duchesne, Gargi Kothari, Farshad Foroudi, Keen Hun Tai
Publikováno v:
Prostate International
Prostate International, Vol 5, Iss 1, Pp 8-12 (2017)
Prostate International, Vol 5, Iss 1, Pp 8-12 (2017)
Background: Prostate cancer management involves a balance between the risks of cancer death against those from other causes. To evaluate the performance of several comorbidity indices in predicting comorbid death in a prostate cancer radiotherapy coh
Autor:
Gillian M. Duchesne, David Joseph, James W. Denham, Suki Gill, John N. S. Matthews, John Attia, Judy Murray, Annette Haworth, Christopher Oldmeadow, A. Kennedy, Martin A. Ebert, Keen Hun Tai, Sandra Turner, Allison Steigler, Nigel Spry, Elizabeth G. Holliday, Nirdosh Kumar Gogna, Lizbeth Kenny, Brett Delahunt, Hendrick Tan, Rachel Kearvell, Chris Atkinson, David Lamb
Publikováno v:
ResearcherID
The relative effects of radiation dose escalation (RDE) and androgen suppression (AS) duration on local prostatic progression (LP) remain unclear.We addressed this in the TROG 03.04 RADAR trial by incorporating a RDE programme by stratification at ra
Autor:
Sandra Turner, Terry Diamond, Gillian M. Duchesne, Lizbeth Kenny, Christopher Oldmeadow, Brett Delahunt, David Joseph, Nigel Spry, David Lamb, Chris Atkinson, Allison Steigler, Keen Hun Tai, Nirdosh Kumar Gogna, David R. H. Christie, James W. Denham, John N. S. Matthews, John Attia
Publikováno v:
The Lancet Oncology. 15:1076-1089
Summary Background We investigated whether 18 months of androgen suppression plus radiotherapy, with or without 18 months of zoledronic acid, is more effective than 6 months of neoadjuvant androgen suppression plus radiotherapy with or without zoledr
Autor:
Patrick Cheung, Jackson S.Y. Wu, Charles Catton, Peter Chung, Tom Corbett, Himu Lukka, Mark Levine, Keen Hun Tai, Jean-Paul Bahary, Theodoros Tsakiridis, Stéphane Supiot, Matthew Parliament, Shahida Ahmed, Jim A. Julian, Ian S. Dayes, Jarad Martin, Colin Tang, Padraig Warde, Chu-Shu Gu, Glenn Bauman, Tim Craig
Publikováno v:
Medical Biophysics Publications
Purpose Men with localized prostate cancer often are treated with external radiotherapy (RT) over 8 to 9 weeks. Hypofractionated RT is given over a shorter time with larger doses per treatment than standard RT. We hypothesized that hypofractionation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30308cdeb2e62ac8684eb84d1e5fcad0
https://ir.lib.uwo.ca/biophysicspub/510
https://ir.lib.uwo.ca/biophysicspub/510
Autor:
Chantelle Wilcox, Nirdosh Kumar Gogna, Gillian M. Duchesne, Chris Atkinson, James W. Denham, Martin A. Ebert, Nigel Spry, Keen Hun Tai, Patrick McElduff, Lizbeth Kenny, Brett Delahunt, David Lamb, David Joseph, Sandra Turner, John W. Matthews
Publikováno v:
Radiotherapy and Oncology. 105(2):184-192
Background: The RADAR trial determines whether adjuvant androgen suppression, bisphosphonates and radiation dose escalation for localised prostate cancer (PC) may improve oncologic outcomes. This study examines whether these measures increase rectal
Autor:
Gillian M. Duchesne, Keen Hun Tai, Maroie Barkati, Scott Williams, Sarat Chander, Andrew See, Sylvia van Dyk, Farshad Foroudi
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 82:1889-1896
Purpose There are multiple treatment options for favorable-risk prostate cancer. High-dose-rate (HDR) brachytherapy as a monotherapy is appealing, but its use is still investigational. A Phase II trial was undertaken to explore the value of such trea